Synairgen said full results from the phase 3 SPRINTER trial of its SNG001 have now been published in the peer-reviewed European Respiratory Journal Open Research (ERJOR).
Topline results were released earlier in the year showing the respiratory drug missed its primary endpoints of discharge from the hospital and recovery, but there were signs of a reduction in the relative risk (RRR) of progression to severe disease.
The full title of the online publication is: "Nebulised interferon beta-1a (SNG001) in hospitalised COVID-19: SPRINTER Phase III Study" and can be accessed here.
Phillip Monk, CSO of Synairgen, added: "The results from the SG016 Phase 2 and the SPRINTER trial of SNG001 in hospitalised patients, and the ACTIV-2 trial in the home setting suggest that SNG001 may be preventing progression to severe disease.
“With these data, we remain confident in the potential of SNG001 as a broad-spectrum antiviral for high-risk patient populations infected with respiratory viruses including influenza and RSV and are focused on its continued clinical development."